Geoffrey Chupp
Associate Program Director · Yale-New Haven Hospital
Credentials: · · · · · ·
History
- Present
- Present
Yale Center for Asthma and Airways Disease (YCAAD) · Yale-New Haven Hospital
- Present
Pulmonary Function Laboratory · Yale-New Haven Hospital
2014–2017- 2017
1993–1997- 1989–1993
1988–1991
1983–1986- 1986
Research
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
New England Journal of Medicine · 2021 · 844 citations
Asthma: mechanisms of disease persistence and progression
Review · Annual Review of Immunology · 2004 · Last of 3 authors · 638 citations
The Lancet Respiratory Medicine · 2017 · First of 9 authors · Corresponding · 500 citations
- JE
19 papers
- LC
17 papers
16 papers
- RH
12 papers
11 papers
9 papers
- EI
9 papers
- CB
8 papers · 1 as a fellow
Grants
- 2022–2027
Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
National Heart, Lung, and Blood Institute · R01
PI · $8.4M · University of California, San Diego
- 2014–2020
Pre-Clinical Development of a Novel Anti-YKL-40 Biologic to Treat Severe Asthma
National Heart, Lung, and Blood Institute · UH3
Contact PI · $4.5M · Yale University
- 2013–2018
Longitudinal Analysis of Transcriptomic Endophenotypes in Asthma
National Heart, Lung, and Blood Institute · R01
Contact PI · $3.3M · Yale University
- 2014–2016
Pre-Clinical Development of a Novel Anti-YKL-40 Biologic to Treat Severe Asthma
National Heart, Lung, and Blood Institute · UH2
Contact PI · $3.3M · Yale University
Clinical trials
- 2020–2021
Camostat Mesylate in COVID-19 Outpatients
Principal investigator · Completed · Phase 2
Yale University
- 2024–2028
Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
Site PI · Recruiting · Phase 4
University of California, San Diego